FDA 483 - Contract Pharmaceuticals Limited Canada - November 03, 2023

This FDA Form 483 document outlines observations made during an inspection of a facility involved in the production of sterile drug products. The inspection revealed several deficiencies related to quality systems and manufacturing controls.

Observation 1 indicates a failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This suggests potential risks to product sterility due to uncontrolled or unmonitored environmental factors.

Observation 2 highlights that the sterilization process for equipment used in sterile drug product production was not adequately validated. This is a critical finding as it directly impacts the sterility assurance of the final product, potentially leading to contaminated drug products.

Observation 3 notes that the firm did not conduct thorough investigations into discrepancies and failures found in batch production records. This indicates a weakness in their quality system's ability to identify root causes of issues and implement effective corrective and preventive actions (CAPA).

Finally, Observation 4 states that the firm did not maintain complete and accurate records of the cleaning and maintenance of equipment. Inadequate record-keeping for cleaning and maintenance can lead to equipment malfunction, cross-contamination, or ineffective cleaning, all of which can compromise product quality and safety.

These observations collectively point to significant deficiencies in the firm's quality control, validation, investigation, and record-keeping practices, which are fundamental requirements for the manufacturing of sterile drug products.